Rallybio Corporation (RLYB)
RLYB Stock Price Chart
Explore Rallybio Corporation interactive price chart. Choose custom timeframes to analyze RLYB price movements and trends.
RLYB Company Profile
Discover essential business fundamentals and corporate details for Rallybio Corporation (RLYB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Jul 2021
Employees
25.00
Website
https://www.rallybio.comCEO
Stephen Uden M.B,
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
RLYB Financial Timeline
Browse a chronological timeline of Rallybio Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.25.
Earnings released on 7 Aug 2025
EPS came in at -$0.22 falling short of the estimated -$0.20 by -12.82%, while revenue for the quarter reached $212.00K , beating expectations by +217.98%.
Earnings released on 8 May 2025
EPS came in at -$0.21 matching the estimated -$0.21, while revenue for the quarter reached $212.00K .
Earnings released on 13 Mar 2025
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $38.00K , missing expectations by -74.58%.
Earnings released on 7 Nov 2024
EPS came in at -$0.26 surpassing the estimated -$0.36 by +27.78%, while revenue for the quarter reached $299.00K , beating expectations by +298.67%.
Earnings released on 8 Aug 2024
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%, while revenue for the quarter reached $299.00K .
Earnings released on 9 May 2024
EPS came in at -$0.47 surpassing the estimated -$0.50 by +6.00%.
Earnings released on 12 Mar 2024
EPS came in at -$0.50 falling short of the estimated -$0.44 by -13.64%, while revenue for the quarter reached $228.00K .
Earnings released on 9 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.51 by +11.76%.
Earnings released on 8 Aug 2023
EPS came in at -$0.46 surpassing the estimated -$0.48 by +4.17%.
Earnings released on 9 May 2023
EPS came in at -$0.43 surpassing the estimated -$0.50 by +14.00%.
Earnings released on 6 Mar 2023
EPS came in at -$0.46 surpassing the estimated -$0.63 by +26.98%.
Earnings released on 7 Nov 2022
EPS came in at -$0.60 falling short of the estimated -$0.54 by -11.11%.
Earnings released on 8 Aug 2022
EPS came in at -$0.57 surpassing the estimated -$0.61 by +6.56%.
Earnings released on 10 May 2022
EPS came in at -$0.48 matching the estimated -$0.48.
Earnings released on 15 Mar 2022
EPS came in at -$0.42 falling short of the estimated -$0.39 by -7.69%.
Earnings released on 10 Nov 2021
EPS came in at -$0.37 surpassing the estimated -$0.89 by +58.43%.
Earnings released on 9 Sept 2021
EPS came in at -$2.80 matching the estimated -$2.80.
Earnings released on 30 Jul 2021
EPS came in at -$0.60 .
Earnings released on 31 Dec 2020
EPS came in at -$0.47 .
Earnings released on 30 Sept 2020
EPS came in at -$0.32 .
RLYB Stock Performance
Access detailed RLYB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.